MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its participation in the upcoming BIO (Biotechnology ...

The global Clinical Trials market is valued at USD 126.4 billion in 2025 and is projected to reach USD 192.6 billion by 2035, growing at a steady 4.3% CAGR. Demand is being driven by the resurgence of ...

Most cancer deaths happen because the cancer cells become resistant to drugs. Adaptive therapies could fix that.

Background Prior work suggests different interstitial lung diseases (ILDs) that share the radiological usual interstitial pneumonia (UIP) pattern have an overall worse prognosis. However, ...

RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to ...

Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model ...

Although osteoarthritis is receiving more attention in both the research and clinical arenas than ever, all that attention ...

Bowen, A. and Nargundkar, S. (2025) Transformational Strategies to Improve the Clinical Trial and Drug Development Process.

Neurizon Therapeutics (ASX:NUZ) is working to develop a potentially effective treatment for the most common form of MND.

Within weeks of treating patients with CER-1236, the company hopes to start learning about its safety profile and gauge efficacy markers.

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...